Enhancement of Curcumin Bioavailability Via the Prodrug Approach: Challenges and Prospects.
Curcumin is a natural product with many interesting pharmacological properties. However, these are offset by the particularly poor biopharmaceutical properties. The oral bioavailability of curcumin in humans is very low, mainly due to low solubility, poor stability, and extensive metabolism. This has led to multiple approaches to improve bioavailability, including administration of curcumin with metabolism inhibitors, formulation into nanoparticles, modification of the curcumin structure, and development of curcumin prodrugs. In this paper, we focus on the pharmacokinetic outcomes of these approaches. Pharmacokinetic parameters of curcumin after release from prodrugs are dependent on the linker between curcumin and the promoiety, and the release itself may depend on the physiological and enzymatic environment at the site of cleavage. This is an area in which more data are required for rational design of improved linkers. Cytotoxicity of curcumin prodrugs seems to correlate well with cellular uptake in vitro, but the in vivo relevance is uncertain. We conclude that improved experimental and theoretical models of absorption of curcumin prodrugs, development of accurate analytical methods for simultaneous measurement of plasma levels of prodrug and released curcumin, and acquisition of more pharmacokinetic data in animal models for dose prediction in humans are required to facilitate movement of curcumin prodrugs into clinical trials.
Biomedicinal Chemistry Program, Faculty of Pharmaceutical Sciences, Chulalongkorn University, 254 Phayathai Road, Patumwan, Bangkok, 10330, Thailand.
Pahweenvaj
P
Ratnatilaka Na Bhuket
Department of Pharmacology and Pharmaceutical Sciences, University of Southern California, Los Angeles, CA, USA.
Asma
A
El-Magboub
Department of Pharmacology and Pharmaceutical Sciences, University of Southern California, Los Angeles, CA, USA.
Ian S
IS
Haworth
Department of Food and Pharmaceutical Chemistry, Faculty of Pharmaceutical Sciences, Chulalongkorn University, 254 Phayathai Road, Patumwan, Bangkok, 10330, Thailand. pornchai.r@chula.ac.th.
Pornchai
P
Rojsitthisak
D000818:Animals; D001682:Biological Availability; D002626:Chemistry, Pharmaceutical / Q000379:methods; D003474:Curcumin / Q000493:pharmacokinetics*; D065546:Drug Liberation / Q000502:physiology; D006801:Humans; D011355:Prodrugs / Q000493:pharmacokinetics*; D012995:Solubility
D011355:Prodrugs; D003474:Curcumin
J Pharm Sci. 2012 Oct;101(10):3979-88
22833171
Cancer Chemother Pharmacol. 2014 Jun;73(6):1137-46
24760417
Biomed Chromatogr. 2011 Oct;25(10):1144-9
21294139
Carbohydr Polym. 2014 Jan;99:499-507
24274536
Curr Drug Targets. 2012 Dec;13(14):1799-819
23140290
J Drug Target. 2016 Sep;24(8):694-702
26942997
Colloids Surf B Biointerfaces. 2013 Jan 1;101:353-60
23010041
J Med Chem. 2007 Nov 29;50(24):6284-8
17973470
Cancer Res. 2001 Feb 1;61(3):1058-64
11221833
Biochem Pharmacol. 1996 Jan 12;51(1):39-45
8534266
Drug Deliv Transl Res. 2014 Aug;4(4):344-52
25422796
Planta Med. 1998 May;64(4):353-6
9619120
J Drug Target. 2016;24(4):273-93
26066739
J Chromatogr B Analyt Technol Biomed Life Sci. 2016 Oct 15;1033-1034:301-310
27595650
J Pharmacol Exp Ther. 2008 Jul;326(1):196-208
18417733
Eur J Pharm Sci. 2013 May 13;49(2):286-93
23542494
PLoS One. 2012;7(6):e39554
22745783
PLoS One. 2015 Feb 18;10(2):e0117526
25692854
Drug Deliv. 2016 Sep;23 (7):2587-2595
26066393
J Pharm Sci. 2011 Feb;100(2):504-11
20848656
J Pharm Biomed Anal. 1997 Aug;15(12):1867-76
9278892
Clin Cancer Res. 2008 Jul 15;14(14):4491-9
18628464
Pharmazie. 2011 Aug;66(8):570-5
21901978
Curr Pharm Des. 2013;19(11):2047-69
23116312
Diabetes Care. 2012 Nov;35(11):2121-7
22773702
Biofactors. 2013 Jan-Feb;39(1):14-20
22996406
Int J Pharm. 2016 Apr 11;502(1-2):28-37
26784981
J Pharm Sci. 2006 Jun;95(6):1177-95
16639719
Cancer Res Treat. 2014 Jan;46(1):2-18
24520218
Mol Pharm. 2007 Nov-Dec;4(6):807-18
17999464
Eur J Med Chem. 2010 Mar;45(3):1078-86
20034711
Colloids Surf B Biointerfaces. 2015 Sep 1;133:347-55
26133239
PLoS One. 2011;6(8):e23388
21887247
Pharm Res. 2012 Dec;29(12):3512-25
22961588
Expert Opin Drug Metab Toxicol. 2005 Aug;1(2):175-85
16922635
Eur J Drug Metab Pharmacokinet. 2016 Dec;41(6):777-785
26563392
J Pharm Sci. 2011 Dec;100(12):5206-18
21850703
Nanomedicine (Lond). 2010 Aug;5(6):855-65
20735222
Phytother Res. 2012 Nov;26(11):1719-25
22407780
Life Sci. 2000 Oct 27;67(23 ):2785-93
11105995
Bioanalysis. 2010 Apr;2(4):733-43
21083271
Colloids Surf B Biointerfaces. 2016 Apr 1;140:11-18
26731193
Cancer Epidemiol Biomarkers Prev. 2002 Jan;11(1):105-11
11815407
Carbohydr Polym. 2015 Dec 10;134:167-74
26428113
J Chromatogr B Analyt Technol Biomed Life Sci. 2007 Jun 1;852(1-2):77-84
17280881
J Mol Signal. 2011 Jul 20;6:7
21774804
Biomed Chromatogr. 2011 Jan;25(1-2):258-77
21204113
Acta Pharmacol Toxicol (Copenh). 1978 Aug;43(2):86-92
696348
Eur J Pharm Biopharm. 2015 Feb;90:53-62
25448079
Eur J Med Chem. 2008 Sep;43(9):1837-46
18201805
Eur Neuropsychopharmacol. 2009 Sep;19(9):636-47
19329286
Drug Discov Today. 2001 Apr 1;6(7):357-366
11267922
Curr Drug Deliv. 2008 Oct;5(4):299-302
18855599
Molecules. 2011 Feb 22;16(2):1888-900
21343891
Drug Metab Pharmacokinet. 2012;27(5):466-77
22813719